Azitra, Inc. (AZTR) stock
Close on Nov 11, 2026Market cap $35.47MP/E –Yield –
Azitra, Inc. saw revenue fall 100.0% to $0 over fiscal 2025. Free cash flow was -$11.65M. At the latest close the market valued the company at $35.47M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Sep 30, 2026
Valuation
- Market cap
- $35.47M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 4.84
- Dividend yield
- –
- Free cash flow yield
- -31.50%
Fundamentals
- Revenue
- $0
- Net income
- -$12.46M
- EPS, diluted
- -$22.50
- Free cash flow
- -$11.65M
- Book value per share
- $0.43
- Diluted shares
- 10M
Trading
- Next earnings
- Nov 11, 2026 (estimated, after the close)
- Previous close
- $0.60
- Open
- $0.60
- Day's range
- $0.59 – $0.62
- Volume
- 71,016
- Average volume (20 days)
- 12,508,557
- Beta (5 years)
- -2.22
- 52-week range
- $0.05 – $3.80
- RSI (14 days)
- 47.8
- Volatility (1 year)
- 4822.8%
- Relative volume
- 0.02×
- WACC
- 7.4%
Market cap history
Month-end market cap since 2023, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | AZTR | S&P 500 | Difference | AZTR per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -54.9% | -2.4% | −52.5 pts | ||
| 3 months | +308.9% | -1.2% | +310.1 pts | ||
| Year to date | +121.0% | +12.3% | +108.7 pts | ||
| 1 year | +47.4% | +12.4% | +35.0 pts | ||
| 3 years | -99.8% | +78.8% | −178.6 pts | -88.1% | +21.4% |
Five years at a glance
Fiscal years 2021 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Azitra filed with the SEC as exhibits to Form 8-K or 6-K
- News
- News
- News
- News
- Update
- News
About Azitra
Pharmaceutical Preparations
Azitra, Inc. is an early-stage clinical biopharmaceutical company that develops innovative therapies for precision dermatology using engineered proteins and topical live biotherapeutic products. The company focuses on genetically engineering commensal skin bacteria, primarily Staphylococcus epidermidis, to deliver therapeutic proteins and living organisms into deeper skin layers. Its product candidate pipeline includes ATR-12 for treating Netherton syndrome, ATR-04 for papulopustular rash caused by epidermal growth factor receptor inhibitor cancer therapies, and ATR-01 for ichthyosis vulgaris. Azitra serves patients suffering from rare, chronic, and treatment-induced dermatologic conditions.
Company profile, executives and historyAzitra stock: common questions
What is Azitra's stock price?
AZTR closed at $0.59 on Nov 11, 2026, down 2.47% on the day. Over the past 52 weeks it traded between $0.05 and $3.80.
What is Azitra's market cap?
Azitra was worth $35.47M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is AZTR's P/E ratio?
Azitra lost money over fiscal 2025 (diluted EPS -$22.50), so it has no meaningful P/E ratio.
How much revenue does Azitra make?
Azitra reported revenue of $0 for fiscal 2025, down 100.0% from a year earlier.
Does Azitra pay a dividend?
No. Azitra has not paid a cash dividend over the last twelve months.
When does Azitra report earnings next?
Azitra is expected to report Q3 FY2026 results on Nov 11, 2026, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has AZTR stock performed over the past year?
Including dividends, AZTR returned +47.4% over the past year, against +12.4% for the S&P 500.
How many AZTR shares are sold short?
0M shares were sold short at the latest FINRA report, 0.56% of the float, or 1.0 days of average trading volume.
Who are Azitra's competitors?
Companies most similar to Azitra by business, industry and size include SYBX, GNLX, KPRX, CRVO, SKVI.
See a number that looks wrong?